Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 15/20 | 0.46 |
| ▸ | CALCR | P30988 | 15/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957282 | 0.95 | EPHA2 (0.49) | RAMP3CALCREPHA2MAPK8MAPK9 | |
| SCHEMBL30957281 | 0.93 | MAPK8 (0.47) | RAMP3CALCREPHA2MAPK8MAPK9 | |
| SCHEMBL14028315 | 0.93 | RAMP3 (0.46) | RAMP3CALCR | |
| SCHEMBL30957280 | 0.92 | RAMP3 (0.46) | RAMP3CALCR | |
| SCHEMBL30868635 | 0.88 | KEAP1 (0.45) | RAMP3CALCREPHA2 | |
| SCHEMBL29905998 | 0.88 | KEAP1 (0.45) | RAMP3CALCREPHA2 | |
| SCHEMBL30868651 | 0.87 | KEAP1 (0.44) | RAMP3CALCREPHA2 | |
| SCHEMBL30868640 | 0.87 | NMUR2 (0.44) | RAMP3CALCRMAPK8MAPK9MAPK10 | |
| SCHEMBL31265332 | 0.86 | ACE (0.43) | EPHA2OPRM1OPRK1 | |
| SCHEMBL30525426 | 0.86 | EPHA2 (0.51) | RAMP3CALCREPHA2OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | JENIUS PHARMA LLC (US) | 2025-12-18 | — | — | US | claimed |
| EP-4389216-A2 | PEPTIDE COMPOSITIONS AND THERAPEUTIC USES | Allegro Pharmaceuticals, LLC (US) | 2024-06-26 | — | — | EP | claimed |
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | JENIUS PHARMA LLC (US) | 2025-12-18 | — | — | US | disclosed |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | JENIUS PHARMA, LLC (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4389216-A2 | PEPTIDE COMPOSITIONS AND THERAPEUTIC USES | Allegro Pharmaceuticals, LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | Allegro Pharmaceuticals, LLC | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132542-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | RAMP3 4038/4885CALCR 3001/4885EPHA2 4332/4885 |
| US-12454549-B2 | Treatments for diseases and disorders that involve oxidative stress | GPX4, GPX1, TXNRD2 | RAMP3 4038/4885CALCR 3001/4885EPHA2 4332/4885 |
| US-20250382328-A1 | TREATMENTS FOR DISEASES AND DISORDERS THAT INVOLVE OXIDATIVE STRESS | GPX4, GPX1, TXNRD2 | RAMP3 4038/4885CALCR 3001/4885EPHA2 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.